Analyst Price Target is GBX 220
▲ +95.56% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sourcebio International in the last 3 months. The average price target is GBX 220, with a high forecast of GBX 220 and a low forecast of GBX 220. The average price target represents a 95.56% upside from the last price of GBX 112.50.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Sourcebio International.
Sourcebio International Plc, together with its subsidiaries, provides various laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries in the United Kingdom, Europe, the United States, and internationally. The company's services cover histopathology cancer screening and clinical diagnostic services; DNA sequencing services and precision medicine to pharmaceutical and biotechnology companies, academia, contract research organizations, and other research markets; shelf-life testing services and equipment; and COVID-19 antigen PCR testing services. It also manufactures library clones, direct to consumer home test kits, and blood and tissue serological products; and provides employee testing solutions and venue testing. In addition, the company offers controlled environment storage services and diagnostic and genomic services and products. Sourcebio International Plc was founded in 1999 and is headquartered in Nottingham, the United Kingdom.